TRACON Pharmaceuticals (TCON) Competitors $0.03 -0.01 (-25.98%) (As of 12/2/2024) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrends TCON vs. NEXI, PRFX, TCBP, TFFP, BLPH, SEEL, SMFL, CLVR, VAXX, and NAVBShould you be buying TRACON Pharmaceuticals stock or one of its competitors? The main competitors of TRACON Pharmaceuticals include NexImmune (NEXI), PainReform (PRFX), TC Biopharm (TCBP), TFF Pharmaceuticals (TFFP), Bellerophon Therapeutics (BLPH), Seelos Therapeutics (SEEL), Smart for Life (SMFL), Clever Leaves (CLVR), Vaxxinity (VAXX), and Navidea Biopharmaceuticals (NAVB). These companies are all part of the "pharmaceutical products" industry. TRACON Pharmaceuticals vs. NexImmune PainReform TC Biopharm TFF Pharmaceuticals Bellerophon Therapeutics Seelos Therapeutics Smart for Life Clever Leaves Vaxxinity Navidea Biopharmaceuticals TRACON Pharmaceuticals (NASDAQ:TCON) and NexImmune (NASDAQ:NEXI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment, risk and community ranking. Does the MarketBeat Community favor TCON or NEXI? TRACON Pharmaceuticals received 245 more outperform votes than NexImmune when rated by MarketBeat users. However, 61.11% of users gave NexImmune an outperform vote while only 56.21% of users gave TRACON Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTRACON PharmaceuticalsOutperform Votes26756.21% Underperform Votes20843.79% NexImmuneOutperform Votes2261.11% Underperform Votes1438.89% Do institutionals & insiders believe in TCON or NEXI? 11.6% of TRACON Pharmaceuticals shares are held by institutional investors. Comparatively, 9.9% of NexImmune shares are held by institutional investors. 5.3% of TRACON Pharmaceuticals shares are held by insiders. Comparatively, 14.9% of NexImmune shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media favor TCON or NEXI? In the previous week, TRACON Pharmaceuticals' average media sentiment score of 0.00 equaled NexImmune'saverage media sentiment score. Company Overall Sentiment TRACON Pharmaceuticals Neutral NexImmune Neutral Which has stronger valuation and earnings, TCON or NEXI? TRACON Pharmaceuticals has higher revenue and earnings than NexImmune. NexImmune is trading at a lower price-to-earnings ratio than TRACON Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTRACON Pharmaceuticals$12.05M0.01-$3.59M$3.730.01NexImmuneN/AN/A-$32.34M-$18.54-0.01 Do analysts rate TCON or NEXI? TRACON Pharmaceuticals presently has a consensus price target of $60.00, suggesting a potential upside of 186,235.40%. Given TRACON Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe TRACON Pharmaceuticals is more favorable than NexImmune.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TRACON Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00NexImmune 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is TCON or NEXI more profitable? TRACON Pharmaceuticals' return on equity of -237.65% beat NexImmune's return on equity.Company Net Margins Return on Equity Return on Assets TRACON PharmaceuticalsN/A -237.65% 57.29% NexImmune N/A -534.32%-213.72% Which has more volatility & risk, TCON or NEXI? TRACON Pharmaceuticals has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500. Comparatively, NexImmune has a beta of 1.68, indicating that its stock price is 68% more volatile than the S&P 500. SummaryTRACON Pharmaceuticals beats NexImmune on 10 of the 13 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Get TRACON Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TCON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCON vs. The Competition Export to ExcelMetricTRACON PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$110,000.00$2.94B$5.14B$9.08BDividend YieldN/A1.90%5.09%4.23%P/E Ratio0.0146.7390.0517.20Price / Sales0.01415.011,117.09117.04Price / Cash0.02182.1043.1037.85Price / Book-0.093.894.784.78Net Income-$3.59M-$42.21M$120.31M$225.60M7 Day PerformanceN/A-2.15%-1.92%-1.23%1 Month PerformanceN/A1.73%13.65%0.46%1 Year PerformanceN/A16.36%28.34%15.24% TRACON Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCONTRACON Pharmaceuticals0.9646 of 5 stars$0.03-26.0%$60.00+186,235.4%-99.1%$110,000.00$12.05M0.0120Gap DownNEXINexImmuneN/A$0.30+30.4%N/A-89.7%$418,000.00N/A-0.016PRFXPainReform1.7798 of 5 stars$2.90-6.8%$8.00+175.9%-47.6%$406,000.00N/A-0.024News CoverageGap UpTCBPTC Biopharm2.9794 of 5 stars$0.55+3.3%$3.00+449.2%-97.4%$289,000.00$4.76M0.0041News CoverageGap DownTFFPTFF Pharmaceuticals2.1554 of 5 stars$0.07flat$44.00+67,592.3%N/A$289,000.00$730,000.00-0.0119Positive NewsBLPHBellerophon Therapeutics0.8474 of 5 stars$0.02+55.7%N/A-62.5%$232,000.00$5.64M-0.0220Dividend AnnouncementAnalyst ForecastNews CoverageGap DownSEELSeelos TherapeuticsN/A$0.30-14.5%N/A-99.8%$110,000.00$2.20M0.0020SMFLSmart for LifeN/A$0.01+14.9%N/A-99.9%$82,000.00$8.23M0.00110Gap DownCLVRClever LeavesN/A$0.03flatN/A-100.0%$48,000.00$17.42M0.00560VAXXVaxxinityN/A$0.00+100.0%N/A-100.0%$25,000.00$70,000.000.0090NAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-99.8%$10,000.00$8,126.000.0010Analyst Forecast Related Companies and Tools Related Companies NexImmune Competitors PainReform Competitors TC Biopharm Competitors TFF Pharmaceuticals Competitors Bellerophon Therapeutics Competitors Seelos Therapeutics Competitors Smart for Life Competitors Clever Leaves Competitors Vaxxinity Competitors Navidea Biopharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TCON) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TRACON Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TRACON Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
